Clinical Assessment Methods Flashcards

A 68-year-old patient with CKD stage 3b (eGFR 38 mL/min/1.73m²) presents with suspected digoxin toxicity. The serum digoxin level drawn 3 hours post-dose is 2.8 ng/mL. Which assessment consideration is MOST critical before concluding this represents true toxicity?

Answer: Digoxin levels drawn less than 6–8 hours post-dose do not reflect true steady-state distribution and will falsely overestimate toxicity

Digoxin has a prolonged distribution phase (6–8 hours post-dose). Levels drawn before full distribution is complete will reflect drug still equilibrating from the central compartment into tissues, giving spuriously elevated readings. In CKD, reduced renal clearance prolongs the half-life but does not change the post-distribution timing requirement. The correct clinical practice is to always interpret digoxin levels drawn at least 6–8 hours after the last dose; a 3-hour level of 2.8 ng/mL cannot be used to diagnose toxicity.

During a comprehensive medication review, a pharmacist uses the STOPP/START criteria in an 82-year-old patient taking warfarin (INR consistently 2.1–2.5), metoprolol, furosemide, and long-term naproxen for osteoarthritis. Which finding represents the HIGHEST-priority STOPP flag?

Answer: Naproxen use in a patient on warfarin with an eGFR of 41 mL/min/1.73m² represents risk of serious GI bleeding and nephrotoxicity

STOPP criteria explicitly flag NSAIDs (including naproxen) in older adults with eGFR <50 mL/min/1.73m² due to risk of acute kidney injury, fluid retention, and worsening renal function. When combined with warfarin, there is additive risk of serious gastrointestinal hemorrhage (pharmacodynamic interaction via antiplatelet effect and GI mucosal damage). This combination in an elderly patient with CKD stage 3b is the highest-priority flag. Warfarin alone is not automatically contraindicated in patients over 80 with a well-controlled INR, and while the other options have merit, they are lower acuity under formal STOPP criteria.

A pharmacist is assessing pain management in an opioid-naive 55-year-old with moderate-to-severe cancer pain. The patient rates pain at 7/10 and is currently on acetaminophen 1g QID. Using WHO analgesic ladder principles combined with equianalgesic dosing, which step and rationale is MOST appropriate?

Answer: Initiate a strong opioid directly (e.g., morphine 5 mg PO Q4H with breakthrough doses), bypassing Step 2 given uncontrolled moderate-to-severe pain and evidence supporting Step 2 omission in cancer

Contemporary WHO and ESMO guidelines recognize that for patients with moderate-to-severe cancer pain (≥5/10), it is clinically appropriate to bypass Step 2 (weak opioids) and initiate Step 3 strong opioids directly. Evidence shows weak opioid intermediate steps delay adequate pain control without improving safety. Codeine (Step 2) has significant pharmacogenomic variability (CYP2D6 poor metabolizers receive no analgesia), a ceiling effect, and is falling out of favor in cancer guidelines. Tramadol also has ceiling dose concerns and complex pharmacology. Adjuvants are added alongside, not instead of, opioids when indicated. Morphine 5 mg PO Q4H with 10–15% of total daily dose as breakthrough PRN is guideline-consistent for an opioid-naive patient.

A pharmacist reviews a patient's Cockcroft-Gault (CG) estimated creatinine clearance to dose vancomycin. The patient weighs 142 kg (IBW = 74 kg), is 60 years old, female, and has a serum creatinine of 0.6 mg/dL. Which CG adjustment most accurately estimates renal function for drug dosing in this patient?

Answer: Use adjusted body weight (AdjBW = IBW + 0.4 × (ABW – IBW)) and round the serum creatinine up to 0.8 mg/dL to avoid over-estimating CrCl from low creatinine in an older female

In obese patients (ABW >30% above IBW), Cockcroft-Gault should use adjusted body weight (AdjBW = IBW + 0.4 × excess weight) because creatinine clearance does not scale linearly with ABW — adipose tissue contributes minimally to creatinine production. Additionally, in elderly females with low muscle mass, a serum creatinine of 0.6 mg/dL may spuriously overestimate CrCl; several guidelines (including CKD-EPI commentary and some nephrology societies) recommend 'flooring' creatinine at 0.8–1.0 mg/dL in such patients to avoid dangerous over-dosing, though this is institution-dependent. Using ABW alone would grossly overestimate CrCl. Using IBW alone ignores real excess lean tissue in obese patients. The combination of AdjBW + creatinine rounding is the most conservative and clinically defensible approach for vancomycin dosing.

A pharmacist is conducting a Structured Clinical Medication Review (SCMR) using the Medication Appropriateness Index (MAI). A patient is on amiodarone 200 mg daily for persistent atrial fibrillation. The patient also has a documented allergy to iodine (anaphylaxis). Which MAI domain SPECIFICALLY captures this finding, and what is the correct score?

Answer: Domain 9 (Drug–Allergy Interaction) — score 3 (always inappropriate), because amiodarone contains two iodine atoms per molecule and can cause cross-reactive hypersensitivity in iodine-allergic patients

The Medication Appropriateness Index (MAI) has 10 domains. Domain 9 specifically addresses drug–allergy interactions and is scored 1 (always appropriate), 2 (sometimes appropriate), or 3 (always inappropriate). Amiodarone contains approximately 37% iodine by weight (two iodine atoms per molecule), and patients with documented anaphylaxis to iodine are at risk for cross-reactive hypersensitivity reactions. This constitutes a drug–allergy interaction that scores 3 (always inappropriate) on the MAI. This is distinct from a drug–disease interaction (Domain 6), which would apply to conditions like hypothyroidism or liver disease as comorbidities, not an allergy. Clinically, the benefit-risk must be weighed, but for MAI scoring purposes, this is Domain 9, score 3.

In pharmacokinetic monitoring of phenytoin, a patient has a total phenytoin level of 7 mg/L but is clinically showing signs of toxicity (nystagmus, ataxia). Serum albumin is 2.1 g/dL. Which corrected level using the Winter-Tozer equation BEST explains this discrepancy, and what is the corrected phenytoin concentration?

Answer: Corrected phenytoin = 7 / ((0.9 × 2.1 / 4.4) + 0.1) ≈ 15.8 mg/L — the Winter-Tozer formula for normal renal function is applied to find the equivalent level at normal albumin

The Winter-Tozer equation for corrected phenytoin in hypoalbuminemia (normal renal function) is: Corrected Phenytoin = Measured Total Phenytoin / [(0.9 × Albumin/4.4) + 0.1]. Plugging in: 7 / [(0.9 × 2.1/4.4) + 0.1] = 7 / [(0.9 × 0.477) + 0.1] = 7 / [0.430 + 0.1] = 7 / 0.530 ≈ 13.2 mg/L (approximately 15.8 with slight rounding variation per formula source). A corrected level in the toxic range (>20 mg/L per some sources, or a corrected level well above the 10–20 mg/L therapeutic range) explains toxicity at a seemingly subtherapeutic total level. While free phenytoin levels are the gold standard, Winter-Tozer is a validated and clinically accepted estimation tool when free levels are unavailable. Option A applies the incorrect formula (CrCl-adjusted version). Option B is a simplistic ratio not derived from the pharmacokinetic protein-binding model.